A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Pancreatic Ductal Adenocarcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients have histologically confirmed pancreatic ductal adenocarcinoma (PDAC) with metastatic disease. 2) Patients have received at least 2 prior lines of therapy for PDAC in any setting, including at least 1 prior gemcitabine-based therapy and at least 1 prior fluoropyrimidine-based therapy. 3) Patients have received no more than 4 prior lines of cytotoxic or myelosuppressive therapy for PDAC.

You may not be eligible for this study if the following are true:

  • 1) Patients have pancreatic neuroendocrine tumors, lymphoma of the pancreas, acinar pancreatic cancer, or ampullary cancer. 2) Patients have known untreated parenchymal brain metastasis or have uncontrolled central nervous system metastases. 3) Patients have a history of hypersensitivity or severe reaction to either relacorilant or nab-paclitaxel or to similar classes of either drug.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.